Dual Checkpoint Blockade Plus FOLFOX Chemo Tested in Metastatic Colorectal Cancer
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
Summary
This completed Phase 1/2 trial enrolled 57 patients with metastatic colorectal cancer to evaluate the safety and tolerability of combining two immune checkpoint inhibitors — durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) — with standard FOLFOX chemotherapy. Colorectal cancer can suppress the immune system through the PD-1/PD-L1 pathway, allowing tumors to evade attack. Preclinical models suggested that blocking both PD-L1 and CTLA-4 alongside chemotherapy acts synergistically, with dramatically improved survival in mouse models compared to chemotherapy alone. This trial aimed to determine whether this combination is safe enough in humans to pursue further, a critical first step before larger efficacy trials. Results from the completed trial have not yet been published in full.
Detailed Summary
Colorectal cancer remains a leading cause of cancer death worldwide, with metastatic disease driving the vast majority of mortality. Despite advances in chemotherapy, outcomes for metastatic colorectal cancer (mCRC) remain poor, creating urgent need for more effective treatment strategies. Immunotherapy has transformed outcomes in several cancers, but its role in mCRC — particularly in patients without microsatellite instability — remains limited and poorly defined.
This Phase 1/2 trial, sponsored by Centre Georges François Leclerc in France, tested a triple combination: durvalumab (an anti-PD-L1 antibody), tremelimumab (an anti-CTLA-4 antibody), and FOLFOX chemotherapy in 57 patients with metastatic colorectal cancer. The rationale was grounded in preclinical data showing that PD-L1 blockade restores T-cell effector function, and that dual checkpoint inhibition combined with the cytotoxic effects of 5-FU-based chemotherapy may work synergistically to prime and sustain an anti-tumor immune response.
The study's primary focus was safety and tolerability — essential groundwork for a combination that layers two immunotherapy agents onto an already intensive chemotherapy backbone. In mouse models, this combination approach achieved 40% survival rates compared to zero with FOLFOX alone, providing compelling preclinical justification.
The trial ran from August 2017 to January 2023, suggesting a lengthy recruitment and follow-up period. However, full results have not yet been published in peer-reviewed literature as of this summary.
The implications are potentially significant: if tolerable, dual checkpoint blockade combined with chemotherapy could open a new front in mCRC treatment, including in patients not traditionally considered immunotherapy candidates. However, the history of checkpoint inhibitor trials in mCRC urges caution, as many promising combinations have failed to demonstrate meaningful efficacy in unselected populations. Independent replication and full data disclosure are essential.
Key Findings
- Phase 1/2 trial combined durvalumab, tremelimumab, and FOLFOX in 57 mCRC patients to assess safety.
- Preclinical mouse models showed 40% survival with the triple combo versus 0% with FOLFOX alone.
- PD-L1 expression in colorectal tumors is linked to worse prognosis and immune evasion.
- Dual blockade of PD-L1 and CTLA-4 pathways may synergize with 5-FU cytotoxicity.
- Trial completed in January 2023; full safety and efficacy results are not yet published.
Methodology
This was a Phase 1/2 open-label clinical trial enrolling 57 patients with metastatic colorectal cancer. The primary endpoint was safety and tolerability of the triple combination. The study ran over approximately five and a half years at a French oncology center.
Study Limitations
This summary is based on the abstract and clinical trial registration only, as the full study results have not been published. No efficacy or safety outcome data are currently available for evaluation. The small single-center enrollment of 57 patients may limit generalizability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.